Gemina Laboratories Ltd. (GLABF)
Gemina Laboratories Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burnaby, BC, CA. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $3.8M. On trailing twelve-month figures it carries a trailing P/E of -6.12, a net margin of 0.0%. Its beta of -0.07 implies it has historically moved less than the broad market.
Gemina Laboratories Ltd. is a Canadian biotechnology company dedicated to the research, development, and commercialization of in-vitro diagnostics. The firm invents innovative surface functionalization chemistries for identifying pathogens and biomarkers. Among its current projects, Gemina is advancing the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip specifically designed to detect active COVID-19 infections. The company maintains its headquarters in Vancouver, Canada.
Gemina Laboratories Ltd. is most often compared with the following Healthcare names: